Bioconversion Products of Whey by Lactic Acid Bacteria Exert Anti-adipogenic Effect

Ji Soo Lee, In Kyung Hyun, Ji-Won Yoon, Hye-Jin Seo, Seok-Seong Kang^*

Author Information & Copyright ▼

¹Department of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University, Goyang 10326, Korea.

^*Corresponding Author: Seok-Seong Kang, E-mail: sskang@dongguk.edu.

© Copyright 2020 Korean Society for Food Science of Animal Resources. This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: Jun 24, 2020 ; Revised: Aug 04, 2020 ; Accepted: Sep 09, 2020

Published Online: Sep 16, 2020

Abstract

Microbial bioconversion using lactic acid bacteria provides several human health benefits. Although whey and whey-derived bioactive compounds can contribute to an improvement in human health, the potential anti-obesity effect of whey bioconversion by lactic acid bacteria has not been well studied. This study aimed to investigate whether bioconversion of whey by Pediococcus pentosaceus KI31and Lactobacillus sakei KI36 (KI31-W and KI36-W, respectively) inhibits 3T3-L1 preadipocyte differentiation. Both KI31-W and KI36-W reduced intracellular lipid accumulation significantly, without decreasing 3T3-L1 preadipocyte proliferation. In addition, obesity-related transcription factor (peroxisome proliferator-activated receptor g) and genes (adipocyte fatty acid-binding protein and lipoprotein lipase) were down-regulated significantly in 3T3-L1 cells in the presence of KI31-W and KI36-W. Collectively, these results suggest that bioconversion of whey by lactic acid bacteria exhibits anti-adipogenic activity and may be applied as a therapeutic agent for obesity.

Keywords: bioconversion; whey; lactic acid bacteria; obesity; 3T3-L1 preadipocyte